Zymeworks updates 2026 guidance after Theravance acquisition
Zymeworks, a biotechnology company, announced updated 2026 financial guidance and final deal details after acquiring Theravance Biopharma. The deal adds the inhaled drug YUPELRI to Zymeworks’ portfolio and aims to diversify revenue through a mix of product sales and collaboration income while preserving its existing commercial team.
What changed in 2026 guidance
The company now projects total 2026 revenue in a range of $278 million to $292 million. It also projects 2026 Adjusted EBITDA (a measure of profitability) between $114 million and $128 million. These figures reflect the contribution expected from the newly added asset YUPELRI (revefenacin) and ongoing collaboration revenue, as well as the impact of the Theravance acquisition on overall financial performance.
Key facts to understand
YUPELRI is a drug used in treating chronic obstructive pulmonary disease (COPD). By acquiring Theravance Biopharma, Zymeworks gains this product and its associated revenues. The company says YUPELRI is expected to provide a durable, recurring source of revenue and cash flow. The firm will retain its existing commercial organization to support hospital promotion of YUPELRI, indicating continued sales and marketing activity for the drug under the new ownership.
Who is affected by the update
Shareholders and investors receive updated financial targets (revenue and profitability) for 2026. Employees in the commercial organization may continue in their roles to promote YUPELRI in hospital settings. Patients and healthcare providers could see continued access to YUPELRI through Zymeworks’ channels, depending on pricing and distribution decisions tied to the acquisition.
Practical next steps for readers
Monitor company communications and earnings calls for details on how YUPELRI revenue is expected to ramp through 2026. Check for any changes to collaboration agreements or milestones tied to other parts of Zymeworks’ portfolio. If you are an investor, review the updated financial guidance alongside historical performance to gauge how the acquisition affects risk and growth potential. For healthcare providers, stay informed about any changes in product access or hospital promotion responsibilities related to YUPELRI.
Limits of the information and common questions
The update reflects management’s current guidance and the announced acquisition details as of the date released. Guidance can change with market conditions, regulatory developments, or new partnerships. Common questions include how YUPELRI contributes to overall margins, how revenue is categorized (product sales vs. collaboration income), and what milestones remain for other assets in Zymeworks’ pipeline.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- biospace.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.